

SUBJECT INDEX

- A**
- Acetate
 - milk fat synthesis
 - nutritional regulation and, 203, 207-10
- Acetyl CoA carboxylase
 - milk fat synthesis
 - nutritional regulation and, 219-20
- Acne
 - gugulipid and, 307-8
- Adaptinol
 - lutein and zeaxanthin
 - protective role in eye, 190
- Adipocytes
 - hypothalamic control of
 - bone formation and, 403-4
 - metabolic pathway fluxes and, 391-94
- Adipose tissue
 - diabetes type 2 prevalence and, 364-66
- Adolescents
 - iron status and neural functioning, 41, 52-53
- Africa
 - diabetes type 2 prevalence and, 348, 350, 352, 360-61, 365
- African Americans
 - diabetes type 2 prevalence and, 356
 - diabetes type 2 prevention and, 155
 - diet of US poor and minority communities
 - 100 years ago, 81, 84-87
- Age-related macular degeneration (AMD)
 - lutein and zeaxanthin
 - protective role in eye, 171, 174, 180, 183-84, 187-93
- Alcohol
 - diabetes type 2 prevention and, 161
 - metabolic pathway fluxes and, 388-90
- Aldose reductase
 - galactosemia and, 70, 75
- Aleuts
 - diabetes type 2 prevalence and, 355
- All-source
 - lipogenesis/lipolysis
 - metabolic pathway fluxes and, 390-91
- Alouatta* spp.
 - diabetes type 2 prevalence and, 349
- American-born poor
 - diet of US poor and minority communities
 - 100 years ago, 81, 90
- Amino acids
 - determination of
 - requirements
 - adult dietary
 - indispensable amino acid requirement, 108-11
 - carbon oxidation techniques, 112
 - childhood essential amino acid requirement, 112
 - conclusions, 112-13
 - data analysis
 - considerations, 108
 - experimental design
 - considerations, 107-8
 - introduction, 102-3
 - methods, 103-6
 - prior adaptation to the level of the test amino acid, 106-7
 - summary, 112-13
 - perioperative patient and nutrition, 268, 271-72
 - selenoprotein synthesis and, 17-34
 - trophic and cytoprotective nutrition for intestine, 229-50
- Anemia
 - iron-deficiency
 - iron status and neural functioning, 41
- Antibiotic resistance
 - foodborne illness reduction and, 326
- Antigen presentation
 - vitamin D and analogs, 117-36
- Antioxidants
 - lutein and zeaxanthin
 - protective role in eye, 181-83, 189-91
 - lutein and zeaxanthin
 - protective role in eye, 171-93
 - perioperative patient and nutrition, 271
 - trophic and cytoprotective nutrition for intestine, 240-42
- Apical transporter
 - dietary iron absorption and, 288
- Apoptosis
 - trophic and cytoprotective nutrition for intestine, 229-50

- Appalachia
 diet of US poor and minority communities
 100 years ago, 81, 87-89
- Arcuate nucleus (ARC)
 hypothalamic control of bone formation and, 406
- Arginine
 perioperative patient and nutrition, 268, 271
 trophic and cytoprotective nutrition for intestine, 229, 238-40
- Arthritis
 gugulipid and, 308
- Aruba
 diabetes type 2 prevalence and, 349
- Asia
 diabetes type 2 prevalence and, 348-49, 361
 diabetes type 2 prevention and, 149
- Aspergillus* spp.
 foodborne illness reduction and, 326
- Astrovirus
 foodborne illness reduction and, 323
- Ateles* spp.
 diabetes type 2 prevalence and, 349
- Australopithecus*
 diabetes type 2 prevalence and, 350
- Autoimmunity
 vitamin D and immune activation, 117, 128-29, 135-36
- Avoparcin
 foodborne illness reduction and, 326
- Ay mice
 hypothalamic control of bone formation and, 407
- Ayurvedic medicine
 gugulipid and, 303-10
- A-ZIP/F1 transgenic mice
 hypothalamic control of bone formation and, 405
- B**
- Bacillus cereus*
 foodborne illness reduction and, 319, 327-28
- Bacteria
 foodborne illness reduction and, 315-41
 metabolic engineering of metabolic pathway fluxes and, 381-82
 milk fat synthesis
 nutritional regulation and, 203, 207, 216
 selenoprotein synthesis and, 26
- Bahrain
 diabetes type 2 prevalence and, 349
- Barbados
 diabetes type 2 prevalence and, 349
- Barrier function
 trophic and cytoprotective nutrition for intestine, 229-50
- Basolateral transfer
 dietary iron absorption and, 289-91
- Bermuda
 diabetes type 2 prevalence and, 349
- β -blockers
 gugulipid and, 308
 hypothalamic control of bone formation and, 403, 408-9
- Bile acid receptor
 gugulipid and, 303, 309-10
- Biohydrogenation theory
 milk fat synthesis
 nutritional regulation and, 214, 216-20
- Biological legacy
 diabetes type 2 prevalence and, 353-55
- Biosynthetic flux
 measurements
 multiple concurrent metabolic pathway fluxes and, 379
- Blacks
 diabetes type 2 prevalence and, 356
 diabetes type 2 prevention and, 155, 157
 diet of US poor and minority communities
 100 years ago, 81, 84-87
- Blindness
 lutein and zeaxanthin protective role in eye, 171, 190-91
- Blue light absorption
 lutein and zeaxanthin protective role in eye, 171, 179-80, 183, 185-86, 190, 191
- B lymphocytes
 vitamin D and immune activation, 117, 124-25
- Body fat
 diabetes type 2 prevention and, 147-48, 154
- Body weight
 gugulipid and, 308
 hypothalamic control of bone formation and, 403-6, 408-9
- Bone
 hypothalamic control of bone formation and, 403-9
 vitamin D and immune activation, 117, 132
- Botswana
 diabetes type 2 prevalence and, 360

- Botulism toxin
 foodborne illness reduction
 and, 319
- Bowel resection
 trophic and cytoprotective
 nutrition for intestine, 229
- Brain
 galactosemia and, 59, 74
 hypothalamic control of
 bone formation and,
 403-9
 iron status and neural
 functioning, 41-53
- Brazil
 diabetes type 2 prevalence
 and, 348
- British Virgin Islands
 diabetes type 2 prevalence
 and, 349
- Butyrate
 milk fat synthesis
 nutritional regulation and,
 203, 207, 208-10
- Butyrivibrio fibrosolvens*
 milk fat synthesis
 nutritional regulation and,
 216
- C**
- Cachexia
 perioperative patient and
 nutrition, 273-74
- Caenorhabditis elegans*
 selenoprotein synthesis
 and, 27
- Calcineurin inhibitors
 vitamin D and immune
 activation, 133
- Calcium
 diabetes type 2 prevention
 and, 161
 vitamin D and immune
 activation, 117, 132,
 134
- Calorically dense/low-
 fiber/high-glycemic
 foods
- diabetes type 2 prevalence
 and, 345
- Campylobacter* spp.
 foodborne illness reduction
 and, 316, 319, 325-37
- Canada
 diabetes type 2 prevalence
 and, 350
 foodborne illness reduction
 and, 331
- Cancer
 perioperative patient and
 nutrition, 264, 266, 269,
 273-74
- Candida albicans*
 foodborne illness reduction
 and, 326
- Carbohydrates
 dietary
 diabetes type 2
 prevention and,
 157-59, 162
 metabolic pathway
 fluxes and, 379, 383-88
- Carbon dioxide (CO₂)
 galactosemia and, 63-64
- Carbon oxidation techniques
 amino acid requirement
 determination and, 101,
 103, 105-6, 109, 111-13
- Caribbean region
 diabetes type 2 prevalence
 and, 349, 359
- β -Carotene
 diabetes type 2 prevention
 and, 159-60
 lutein and zeaxanthin
 protective role in eye,
 177, 189-90, 192
- Carotenoids
 diabetes type 2 prevention
 and, 159-60
 lutein and zeaxanthin
 protective role in eye,
 171-93
- Cataracts
 galactosemia and, 73
- lutein and zeaxanthin
 protective role in eye,
 189-90
- Caucasians
 diabetes type 2 prevention
 and, 155, 157
- Cayman Islands
 diabetes type 2 prevalence
 and, 349
- Cell differentiation
 trophic and cytoprotective
 nutrition for intestine,
 229-50
 vitamin D and immune
 activation, 135
- Cell migration
 trophic and cytoprotective
 nutrition for intestine,
 229-50
- Cell proliferation
 metabolic pathway fluxes
 and, 391-95
 trophic and cytoprotective
 nutrition for intestine,
 229-50
- Cell recruitment
 vitamin D and immune
 activation, 135
- Cellular retinoic acid binding
 protein (CRABP)
 history of research, 12-13
- Cellular retinol binding
 protein (CRBP)
 history of research,
 12-13
- Central mediation
 hypothalamic control of
 bone formation and,
 405-6
- Central obesity
 diabetes type 2 prevention
 and, 153-54
- Cerebellum
 iron status and neural
 functioning, 43, 48
- Chemotherapy
 trophic and cytoprotective

- nutrition for intestine,
 235-38, 242, 245
- Children**
 amino acid requirement
 determination and, 101,
 112
 diabetes type 2 prevalence
 and, 345, 348-49, 366
 iron status and neural
 functioning, 41-42, 51
- Chile**
 diabetes type 2 prevalence
 and, 360
- China**
 diabetes type 2 prevalence
 and, 348, 359, 361, 365
 diabetes type 2 prevention
 and, 149, 151, 154
 selenoprotein synthesis
 and, 19
- Cholesterol**
 gugulipid and, 303-10
- Chorioretinal changes**
 lutein and zeaxanthin
 protective role in eye, 191
- Choroidemia**
 lutein and zeaxanthin
 protective role in eye, 190
- Choroid plexus**
 iron status and neural
 functioning, 44
- Chromatic aberration**
 lutein and zeaxanthin
 protective role in eye,
 179-80
- Chromium**
 diabetes type 2 prevention
 and, 160
- Chytil F, 1-14**
- Cicer arietinum*
 gugulipid and, 307
- cis*-acting sequences
 selenoprotein synthesis
 and, 17-18, 21, 24-26
- Clofibrate**
 gugulipid and, 307
- Clostridium* spp.
 foodborne illness reduction
 and, 318-19, 327
- Cognate immunity**
 vitamin D and immune
 activation, 118-19
- Cognitive dysfunction**
 galactosemia and, 59, 74
- Cold tolerance**
 foodborne illness reduction
 and, 328-29
- Collagen**
 hypothalamic control of
 bone formation and,
 405
- Color filter**
 lutein and zeaxanthin
 protective role in eye,
 171, 179-80
- Commiphora mukul*
 gugulipid and, 303-10
- Congo**
 diabetes type 2 prevalence
 and, 365
- Conjugated linoleic acid**
 (CLA)
 milk fat synthesis
 nutritional regulation and,
 203, 214-20
- Consolidation in food**
 industry
 foodborne illness reduction
 and, 330
- Cortex**
 iron status and neural
 functioning, 43, 48, 50
- Corticosteroids**
 vitamin D and immune
 activation, 133-34
- Costa Rica**
 iron status and neural
 functioning, 50
- Cost/benefit analysis**
 foodborne illness reduction
 and, 315
- perioperative patient and
 nutrition, 264, 271-73
- Cross-talk**
 vitamin D and immune
 activation, 118-19
- Cryptococcus neoformans*
 foodborne illness reduction
 and, 326
- Cryptosporidium parvum*
 foodborne illness reduction
 and, 322, 325, 337
- Cyclic adenosine**
 monophosphate (cAMP)
 history of research, 1, 9-10
 hypothalamic control of
 bone formation and, 408
- Cyclospora cayetanensis*
 foodborne illness reduction
 and, 322, 325, 331, 337
- Cyclosporine**
 vitamin D and immune
 activation, 133
- Cytochrome P450 genes**
 gugulipid and, 308
- Cytokines**
 vitamin D and immune
 activation, 133
- Cytoprotective nutrition**
 trophic and cytoprotective
 nutrition for intestine,
 229-50
- Czech Republic**
 diabetes type 2 prevalence
 and, 349

D

- Dark adaptation**
 decreased
 lutein and zeaxanthin
 protective role in eye,
 190
- db/db* mice
 hypothalamic control of
 bone formation and, 405
- DCT1 transporter**
 dietary iron absorption and,
 283, 288
- Dcytb* gene
 dietary iron absorption and,
 283, 288-89

- Dendritic cells
 vitamin D and immune activation, 117, 120–22, 135–36
- De novo lipogenesis (DNL)
 metabolic pathway fluxes and, 384–88
- Developed countries
 diabetes type 2 prevalence and, 345–50, 358–63, 365–66
- Developing countries
 diabetes type 2 prevalence and, 345–46, 348–50, 359–62, 365–66
- Developmental delay
 iron status and neural functioning, 41–53
- Dexamethasone
 vitamin D and immune activation, 127, 133–34
- Diabetes type 2 prevalence
 adipose tissue, 364–66
 adults, 347–66
 biological legacy, 353–55
 children, 348–49, 366
 definition, 346–47
 diagnosis, 346–47
 diversity, 361–62
 early hominid diets and lifeways, 351–52
 energetics, 360–61
 etiology, 346–47
 evolutionary theories, 355–58
 evolutionary trends, 349–55
 food preferences, 354–55
 food production, 360–61
 globalization, 361–62
 glycemic index, 363–64
 input, 361
 insulin resistance
 metabolic syndrome, 357
 introduction, 346–47
 modernization of diets, 359–64
 movement
 transportation, 360
 natural selection for fatness and fat infants, 353–54
 Neolithic transitions in diet and lifeways, 352–53
 new food systems, 359–64
 New World syndrome, 356
 nonhuman primates, 349–51
 obesity, 364–66
 output, 360–61
 overview, 346–47
 paleonutrition, 351–52
 patterns of food ingestion, 362–63
 positive energy balance, 364–66
 prenatal phenotypic programming, 357–58
 subsistence energy costs, 360–61
 summary, 366
 supersizing foods, 362
 Syndrome X, 357
 taste, 354–55
 thrifty genotypes, 355–56
 worldwide prevalence, 347–49
 prevention
 anthropometric factors, 148–51
 central obesity, 153–54
 conclusions, 161–62
 diagnostic factors, 148–51
 dietary carbohydrate, 157–59
 dietary fat, 154–57
 dietary fiber, 157–58
 dietary protein, 159
 energy balance, 149, 152–54
 ethanol, 161
 fruits, 159–60
 glycemic index, 158–59
 introduction, 148
 metabolic factors, 148–51
 micronutrients, 160–61
 nutritive sweeteners, 158
 overall obesity, 152–53
 physical activity, 154
 S₁, 154–56
 starch, 158
 summary, 161–62
 vegetables, 159–60
- Dietary essential amino acids
 amino acid requirement determination and, 101
- Dietary globalization
 diabetes type 2 prevalence and, 345–66
- Diltiazem
 gugulipid and, 308
- Direct amino acid oxidation (DAAO) and 24-h balance
 amino acid requirement determination and, 101, 103–4, 108–10, 112
- Diversity
 diabetes type 2 prevalence and, 361–62
- DMT1 transporter
 dietary iron absorption and, 283, 288
- DNA synthesis
 metabolic pathway fluxes and, 379, 391–395
- Dopamine
 iron status and neural functioning, 41, 46

- Dopamine β -hydroxylase
hypothalamic control of
bone formation and,
408
- Drosophila melanogaster*
selenoprotein synthesis
and, 27
- Drug metabolism
gugulipid and, 307–10
- E**
- eEFsec elongation factor
selenoprotein synthesis
and, 27
- Egypt
diabetes type 2 prevalence
and, 348
iron status and neural
functioning, 52
- Elderly
lutein and zeaxanthin
protective role in eye,
171–93
- Endocrine control
hypothalamic control of
bone formation and,
403–9
- Energy balance
diabetes type 2 prevalence
and, 360–61
diabetes type 2 prevention
and, 149, 152–54
- England
diabetes type 2 prevalence
and, 358
- Enteral nutrition
perioperative patient and
nutrition, 263–64, 266–74
- Enterococcus* spp.
foodborne illness reduction
and, 326–27
- Epidemiology
lutein and zeaxanthin
protective role in eye,
188–91
- Escherichia coli*
foodborne illness reduction
and, 318, 320, 325,
328–29, 337–38
history of research, 1, 9
selenoprotein synthesis
and, 21, 23–24, 31
- Eskimos
diabetes type 2 prevalence
and, 355
- Essential amino acids
amino acid requirement
determination and,
101–13
- Ethanol
diabetes type 2 prevention
and, 161
metabolic pathway fluxes
and, 388–90
- Eukaryotes
selenoprotein synthesis
and, 24–31
- Eurasia
diabetes type 2 prevalence
and, 361
- Europe
diabetes type 2 prevalence
and, 361
foodborne illness reduction
and, 326
- European immigrants
diet of US poor and
minority communities
100 years ago, 91–94
- Evolution
diabetes type 2 prevalence
and, 345–66
- Extracellular matrix
hypothalamic control of
bone formation and,
404–5
- Eye
lutein and zeaxanthin
protective role in, 171–93
- F**
- Farnesoid X receptor (FXR)
gugulipid and, 303,
309–10
- Fatness
diabetes type 2 prevalence
and, 353–54
- Fats
dietary
diabetes type 2
prevention and,
154–57, 162
metabolic pathway
fluxes and, 379, 383–84
milk fat synthesis
nutritional regulation and,
203–20
- Fatty acids
milk fat synthesis
nutritional regulation and,
203–20
trophic and cytoprotective
nutrition for intestine,
229, 243–48
- Fatty acid synthase
milk fat synthesis
nutritional regulation and,
219–20
- Federal responsibilities
foodborne illness reduction
and, 335
- Ferric reductase
dietary iron absorption and,
288–89
- Ferritin
iron status and neural
functioning, 44
- Ferroportin
dietary iron absorption and,
288
- Fiber
dietary
diabetes type 2
prevention and,
157–58, 162
milk fat synthesis
nutritional regulation
and, 207–11, 213,
215–20
trophic and
cytoprotective nutrition

- for intestine, 229, 245-48
- Finland
 - diabetes type 2 prevention and, 152, 156, 160
- Flux measurement
 - metabolic pathway fluxes and, 379-99
- Foodborne illness
 - antibiotic resistance, 326
 - approaches to reducing illness, 337-40
 - better outbreak detection, 337-38
 - calls for change, 335-36
 - chronic sequelae of infection, 325-26
 - cold tolerance, 328-29
 - complexity of food safety network, 331-32
 - conclusions, 340-41
 - consolidation in food industry, 330
 - detection of
 - microorganisms in food and patient specimens, 324
 - divided regulatory responsibilities, 333-35
 - education, 338-39
 - emergence of new foodborne pathogens, 324-25
 - federal responsibilities, 335
 - foodborne pathogens yet to be identified, 325
 - food processing, 326-29
 - government
 - responsibilities, 332-33, 335
 - heat/acid resistance, 327-28
 - imported foods, 330-31
 - infectious dose estimates, 318-24
 - information, 338-39
 - intentional contamination, 336
 - introduction, 317-18
 - large facilities, 330
 - local responsibilities, 335
 - minimally processed foods, 329
 - multiple interventions, 329
 - overview, 316-17
 - population surveillance, 337-38
 - prevention-based
 - regulatory approaches, 338
 - private sector
 - responsibilities, 332-33
 - raw foods, 329
 - regulatory framework, 332-36
 - resources, 334
 - risk-based system for food safety, 339-40
 - scientific challenges, 318-26
 - small facilities, 330
 - spoilage, 328-29
 - state responsibilities, 335
 - structure of food industry, 330-32
 - very small facilities, 330
 - workforce, 332
- Food ingestion patterns
 - diabetes type 2 prevalence and, 362-63
- Food preferences
 - diabetes type 2 prevalence and, 354-55
- Food processing
 - foodborne illness reduction and, 315, 326-29
- Food production
 - diabetes type 2 prevalence and, 360-61
- Food restriction
 - metabolic pathway fluxes and, 393-94
- Food safety
 - foodborne illness reduction and, 315-41
- Food systems
 - new
 - diabetes type 2 prevalence and, 359-64
- French Canadians
 - diet of US poor and minority communities 100 years ago, 91
- Fruits
 - diabetes type 2 prevention and, 159-60
- Functional genomics
 - metabolic pathway fluxes and, 379-99
- G
 - Galactosemia
 - aldose reductase, 70, 75
 - cataracts, 73
 - chronic brain effects, 74
 - enzymes, 69-73
 - future research, 75-76
 - galactitol, 65
 - galactokinase, 69
 - galactonate, 66
 - galactose, 63, 76
 - galactose-1-phosphate, 65-66
 - galactose-1-phosphate uridylyltransferase, 69
 - human sibling pairs, 75-76
 - introduction, 60-61
 - lactose, 61-63
 - liver, 76
 - magnitude of clinical effect of consumed galactose in humans, 76
 - metabolites, 65-68
 - mice, 75-76
 - modifier gene, 75-76
 - neonatal toxicity, 73-74
 - ovarian failure, 74
 - oxidation to CO₂, 63-64
 - pathophysiologic process, 73-74

- phenotype, 75
 protector gene, 75-76
 summary, 68, 76
 target organs, 76
 UDP-galactose, 66-68
 UDP-galactose-4-epimerase, 71-73
 UDP-glucose, 66-68
 UDP-glucose pyrophosphorylase, 70-71
 uridine controversy, 75
 GALT deficiency
 galactosemia and, 59-76
 Gamma-aminobutyric acid (GABA)
 iron status and neural functioning, 42, 45, 47-53
 Genetically-based
 autoimmune disease
 vitamin D and immune activation, 127-29
 Genomics
 metabolic pathway fluxes and, 379-99
 Ghrelin
 diabetes type 2 prevalence and, 364
Giardia lamblia
 foodborne illness reduction and, 322
 GK genes
 galactosemia and, 69-70
 Globalization
 dietary
 diabetes type 2 prevalence and, 359-64
 diabetes type 2 prevalence and, 345-66
 Glucocorticoids
 history of research, 12-13
 Glucogenic-insulin theory
 milk fat synthesis
 nutritional regulation and, 210-13
 Glucose
 diabetes type 2 prevention and, 147-62
 metabolic pathway fluxes and, 385-88
 perioperative patient and nutrition, 272-73
 Glutamate
 trophic and cytoprotective nutrition for intestine, 229
 Glutamine
 trophic and cytoprotective nutrition for intestine, 229, 232-38
 Glutathione
 trophic and cytoprotective nutrition for intestine, 229, 240-42
 Glycemic index
 diabetes type 2 prevalence and, 363-64
 diabetes type 2 prevention and, 158-59
 Glycine
 trophic and cytoprotective nutrition for intestine, 229, 238
 Glycogen storage disease
 metabolic pathway fluxes and, 382
 Goldthioglucoase
 hypothalamic control of bone formation and, 406, 408
 Government responsibilities
 foodborne illness reduction and, 332-33, 335
 Grenada
 diabetes type 2 prevalence and, 349
 Gugulipid
 animal studies, 305-6
 clinical studies, 306-7
 Commiphora mukul, 304
 farnesoid X receptor, 309
 guggulsterone, 304-5
 history, 304
 hypolipidemic activity, 305-8
 introduction, 303-5
 mechanism of action, 309
 metabolic effects, 305-8
 overview, 303-4
 potential activities, 307-8
 side effects, 309-10
 summary, 310
 toxicity, 309-10
 Gut barrier functions
 trophic and cytoprotective nutrition for intestine, 229-50
 GW4064
 gugulipid and, 309

H
²H₂O labeling
 metabolic pathway fluxes and, 379, 390-91, 395, 398-99
 Haidinger's brushes
 lutein and zeaxanthin protective role in eye, 180-81
 Hawaii
 diabetes type 2 prevention and, 149
 Hazard Analysis and Critical Control Points (HACCP) system
 foodborne illness reduction and, 338-40
 Heat/acid resistance
 foodborne illness reduction and, 327-28
 Heme iron absorption
 dietary iron absorption and, 284-85
 Hepatitis A virus (HAV)
 foodborne illness reduction and, 323
 Hepcidin
 dietary iron absorption and, 294-95

- Heterochromatic flicker photometry (HFP)
lutein and zeaxanthin protective role in eye, 185-86
- HFE protein
dietary iron absorption and, 293-94
- High-performance liquid chromatography (HPLC)
lutein and zeaxanthin protective role in eye, 173, 188
- Histidine
trophic and cytoprotective nutrition for intestine, 238
- Hominids
diabetes type 2 prevalence and, 351-52
- Homo* spp.
diabetes type 2 prevalence and, 350-52
- Hong Kong
diabetes type 2 prevalence and, 349
- Hormones
history of research, 1, 12
hypothalamic control of bone formation and, 403-9
- Humoral mediator
hypothalamic control of bone formation and, 403, 407
- β -Hydroxybutyrate
milk fat synthesis
nutritional regulation and, 209, 211
- Hypercalcemia
vitamin D and immune activation, 132, 134
- Hypolipidemic activity
gugulipid and, 305-8
- Hypothalamus
leptin and bone formation central mediation of
leptin effect on bone mass, 405-6
hormonal regulation of bone remodeling, 404
hypothalamic neurons controlling bone formation and body weight, 406-7
inhibition of bone formation, 404-5
neuronal pathways controlling bone formation and body weight, 406-7
sympathetic nervous system, 407-9
therapeutic implications, 407-9
- Hypothyroidism
gugulipid and, 308
- I**
- Immigrant households
diet of US poor and minority communities
100 years ago, 81, 89-94
- Immune activation
vitamin D and analogs, 117-36
- Imported foods
foodborne illness reduction and, 330-31
- India
amino acid requirement determination and, 107
diabetes type 2 prevalence and, 359, 361
perioperative patient and nutrition, 266
- Indicator amino acid oxidation (IAAO) and 24-h balance
amino acid requirement determination and, 101, 104-13
- Indispensable amino acids
amino acid requirement determination and, 101-13
- Indonesia
diabetes type 2 prevalence and, 348, 362
iron status and neural functioning, 50
- Induced immune-mediated disease
vitamin D and immune activation, 129-30
- Infants
diabetes type 2 prevalence and, 353-54
galactosemia and, 59-76
iron status and neural functioning, 41-42, 49-51
- Infectious dose estimates
foodborne illness reduction and, 318-24
- Inflammation
gugulipid and, 307-8
- Inflammatory bowel disease (IBD)
trophic and cytoprotective nutrition for intestine, 229, 233-34, 241-44
- Innate immunity
vitamin D and immune activation, 118-19, 135
- Insulin
diabetes type 2 prevention and, 147
milk fat synthesis
nutritional regulation and, 207, 210-13
- Insulin resistance metabolic syndrome
diabetes type 2 prevalence and, 357
- Intentional contamination
foodborne illness reduction and, 336
- Interferon- β (IFN- β)
vitamin D and immune activation, 133

Interventional epidemiology
lutein and zeaxanthin
protective role in eye,
189-91

Intestinal adaptation
trophic and cytoprotective
nutrition for intestine,
229-50

Intestinal transit
dietary iron absorption and,
287

Intracerebroventricular (ICV)
infusion
hypothalamic control of
bone formation and, 403,
405-8

Iregl gene
dietary iron absorption and,
283, 289-90

Iron absorption
dietary
apical transporter, 288
basolateral transfer,
289-91
DCT1, 288
Dcytb, 288-89
DMT1, 288
ferric reductase, 288-89
ferroportin, 288
genetics, 292-95
heme iron absorption,
284-85
hepcidin, 294-95
HFE, 293-94
intestinal lumen, 285-88
intestinal transit, 287
introduction, 283-84
Iregl, 289-90
iron speciation in
intestinal lumen,
285-86
iron transport genes,
287-88
ligands, 286
luminal redox reactions,
287
MTP1, 289-90

mucus, 286-88, 292
nonheme iron
absorption, 284
Nramp2, 288
overview of iron
absorption in
mammals, 284-85
pH, 286
regulation, 285-88,
291-92, 294-95
scope of review, 283-84
SLC 11AC, 289-90
summary, 295-96
transfer, 292-93

Iron status
neural functioning and
acute effects, 49-50
adolescents, 52-53
conclusions, 53
function, 45-47
GABA, 47-53
human studies of iron
deficiency, 48
infant studies, 49-51
introduction, 42
location and uptake of
brain iron, 42-45
long-term effects,
50-51
monoamines, 45-47
myelin, 45
neonatal iron deficiency,
49
neurodevelopment,
47-48
oligodendrocytes, 45
preschool children, 51

Isomerization
lutein and zeaxanthin
protective role in eye,
179

Isoproterenol
hypothalamic control of
bone formation and, 408

Italy
diabetes type 2 prevalence
and, 348

J

Japan
diabetes type 2 prevalence
and, 348, 362
diabetes type 2 prevention
and, 149

K

Kidney
gugulipid and, 309-10

Kinetics
selenoprotein synthesis
and, 23-24

Klebsiella pneumoniae
foodborne illness reduction
and, 325-26

Knockdowns
iron status and neural
functioning, 44

Knockouts
galactosemia and, 59
metabolic pathway fluxes
and, 382

L

Lactobacillus spp.
history of research, 6

Lactose
galactosemia and, 59-76

Latin America
diabetes type 2 prevalence
and, 359-61, 365-66
iron status and neural
functioning, 42

Leflunamide
vitamin D and immune
activation, 133

Leptin
diabetes type 2 prevalence
and, 354, 364
hypothalamic control of
bone formation and,
403-9
metabolic pathway fluxes
and, 393-94

Lifestyle changes
diabetes type 2 prevention

- and, 162
 - Ligands
 - dietary iron absorption and, 286
 - gugulipid and, 303-10
 - Light absorption
 - lutein and zeaxanthin protective role in eye, 171, 178-80, 183, 185-86, 190-91
 - Light filter
 - lutein and zeaxanthin protective role in eye, 171, 179-80
 - Lipid pathway dynamics
 - metabolic pathway fluxes and, 379, 384-85
 - Lipids
 - gugulipid and, 303-10
 - milk fat synthesis nutritional regulation and, 203-20
 - trophic and cytoprotective nutrition for intestine, 229
 - Lipofuscin
 - lutein and zeaxanthin protective role in eye, 187
 - Lipogenesis/lipolysis
 - all-source
 - metabolic pathway fluxes and, 390-91
 - Lipoprotein synthesis
 - metabolic pathway fluxes and, 379
 - Listeria monocytogenes*
 - foodborne illness reduction and, 320, 325, 328-29, 337-38
 - Liver
 - galactosemia and, 76
 - gugulipid and, 309-10
 - history of research, 1, 8, 10
 - metabolic pathway fluxes and, 379, 395-98
 - milk fat synthesis nutritional regulation and, 207
 - Local responsibilities
 - foodborne illness reduction and, 335
 - Long-lived protein synthesis
 - metabolic pathway fluxes and, 379, 398
 - Low-fat milk syndrome
 - milk fat synthesis nutritional regulation and, 204-8
 - Low-fiber diets
 - milk fat synthesis nutritional regulation and, 207-11, 213, 215-20
 - Lumen
 - intestinal
 - dietary iron absorption and, 285-88
 - Lutein/zeaxanthin
 - protective role in eye
 - age-related macular degeneration, 189-90
 - aggregation, 177
 - antioxidation, 181-83
 - biological properties, 179-83
 - cataracts, 189-90
 - characterization, 176-77
 - chemical properties, 174-78
 - chromatic aberration, 179-80
 - conclusions, 192-93
 - current
 - recommendations, 192-93
 - dietary sources, 183-84
 - epidemiological evidence, 188-91
 - fluorescence of lipofuscin, 187
 - future recommendations, 193
 - Haidinger's brushes, 180-81
 - heterochromatic flicker photometry, 185-86
 - history, 172-74
 - interventional epidemiology, 189-91
 - introduction, 172-74
 - isomerization, 179
 - light absorption, 178-79
 - light filter, 17-80
 - macular pigment, 172-74
 - macular region of retina, 172-73
 - measurement of macular pigment in vivo, 184-88
 - membrane properties, 180-81
 - miscellaneous eye diseases, 190-91
 - observational epidemiology, 188-89
 - orientation in membranes, 181
 - oxidation, 177
 - oxidation/reduction products, 177-78
 - physical properties, 178-79
 - polarity, 177
 - potential role, 174
 - pro-oxidation, 181-83
 - protective actions, 191-92
 - reactivity, 177
 - reflectometry, 186-87
 - resonance Raman spectroscopy, 187-88
 - solubility, 177, 181
 - sources, 183-84
 - supplements, 184
- M**
- Macronutrient intake
 - metabolic pathway fluxes and, 379
- Macronutrient intake de novo lipogenesis (MIDA)
 - metabolic pathway fluxes

- and, 384–85
- Macrophages
vitamin D and immune activation, 120–22, 135
- Macular degeneration
age-related
lutein and zeaxanthin protective role in eye, 171, 174, 180, 183–84, 187–93
- Magnesium
diabetes type 2 prevention and, 160
- Malnutrition
perioperative patient and nutrition, 263–74
trophic and cytoprotective nutrition for intestine, 229
- Marine oil diets
milk fat synthesis
nutritional regulation and, 207, 209, 217–18
- Mass spectrometry
metabolic pathway fluxes and, 379–99
- Mauritius
diabetes type 2 prevalence and, 349
- MC4R*-deficient mice
hypothalamic control of bone formation and, 405, 407
- Medicare
perioperative patient and nutrition, 268, 272
- Mediterranean region
diabetes type 2 prevalence and, 348
- Megasphaera elsdenii*
milk fat synthesis
nutritional regulation and, 216
- Melanocortin
hypothalamic control of bone formation and, 405–8
- Menopause
hypothalamic control of bone formation and, 403
- Mergers in food industry
foodborne illness reduction and, 330
- Metabolic pathway fluxes
in vivo measurements
adipose tissue
acyl-glycerides, 391–92
adipose tissue lipids and cells, 391–94
all-source lipogenesis and lipolysis, 390–91
cell proliferation, 391–95
CHO surplus, 385–88
comment, 390, 395
conclusions, 398–99
defining operational unit of function, 382–83
de novo lipogenesis, 384–88
depots, 39–92
dietary carbohydrates and fats, 383–84
distal phenotypic consequences of inborn errors of metabolism in humans, 382
DNA synthesis, 391–95
emergent property, 381–82
ethanol, 388–90
food restriction, 393–94
functional genomics, 380–83
genetic analysis of complex diseases or traits, 382
glucose metabolism, 385–88
 $^2\text{H}_2\text{O}$ labeling, 390–91, 395, 398
hepatic VLDL assembly, 395–98
improving observability of fully assembled systems, 383
introduction, 380
knockout mice, 382
leptin, 393–94
lipid pathway dynamics, 384–85
metabolic engineering of bacteria, 381–82
MIDA technique, 384–85
mitochondrial components, 395
ob/ob mice, 391, 393–94
phenotype, 382, 390–91
static concentrations, 383–84
summary, 398–99
tension between whole and parts, 382–83
transgenic mice–82
unpredictability, 381–82
- Metabolism
amino acid requirement determination and, 101, 109
diabetes type 2 prevention and, 148–51
galactosemia and, 65–68
gugulipid and, 305–8
hypothalamic control of bone formation and, 403, 409
iron status and neural functioning, 41, 45–46
milk fat synthesis
nutritional regulation and, 203–4
stress and, 1, 6–7
vitamin D and immune activation, 117
- Metformin
diabetes type 2 prevention and, 151, 153
- Methanococcus jannaschi*
selenoprotein synthesis

- and, 26-27
- Mexican Americans
 - diet of US poor and minority communities
 - 100 years ago, 81, 89
- Mexico
 - diabetes type 2 prevalence and, 348-49
- Microbes
 - foodborne illness reduction and, 315-41
 - milk fat synthesis
 - nutritional regulation and, 203, 207, 216
- Micronutrients
 - diabetes type 2 prevention and, 160-62
- Middle East
 - diabetes type 2 prevalence and, 348-49, 361, 366
- Milk fat synthesis
 - nutritional regulation of acetate, 208-10
 - background, 205-8
 - biohydrogenation theory, 216-20
 - butyrate, 208-10
 - conclusions, 220
 - fatty acid origins, 205-6
 - glucogenic-insulin theory, 210-13
 - introduction, 204
 - low-fat milk syndrome, 206-8
 - milk fat depression, 208-16
 - rumen, 20-10
 - trans* fatty acid theory, 214-16
- Minimally processed foods
 - foodborne illness reduction and, 329
- Minority households
 - diet of US poor and minority communities
 - 100 years ago, 81-97
- Mitochondria
 - metabolic pathway fluxes and, 395
- Modernization
 - diabetes type 2 prevalence and, 345-66
- Modifier gene
 - galactosemia and, 75-76
- Monoamines
 - iron status and neural functioning, 45-47
- Monocytes
 - vitamin D and immune activation, 120-22
- Monosodium glutamate (MSG)
 - hypothalamic control of bone formation and, 406, 408
- Mountaineers
 - diet of US poor and minority communities
 - 100 years ago, 87-89
- Movement transportation
 - diabetes type 2 prevalence and, 360
- MTPL* gene
 - dietary iron absorption and, 289-90
- Mucus
 - dietary iron absorption and, 286-88, 292
 - trophic and cytoprotective nutrition for intestine, 229-50
- Mycophenolate mofetil
 - vitamin D and immune activation, 133
- Myelin
 - iron status and neural functioning, 41, 45
- Myopia
 - lutein and zeaxanthin protective role in eye, 191
- N
 - Native Americans
 - diabetes type 2 prevalence and, 355-56
 - Natural killer (NK) cells
 - vitamin D and immune activation, 124-25
 - Natural selection
 - diabetes type 2 prevalence and, 353-54
 - Near East
 - diabetes type 2 prevalence and, 352
 - Neolithic transitions
 - diabetes type 2 prevalence and, 352-53
 - Neomercazole
 - gugulipid and, 308
 - Neonatal iron deficiency
 - iron status and neural functioning, 49
 - Neonatal toxicity
 - galactosemia and, 73-74
 - Netherlands
 - diabetes type 2 prevention and, 156
 - perioperative patient and nutrition, 268
 - Neural functioning
 - iron status and, 41-53
 - Neurodevelopment
 - iron status and neural functioning, 41, 47-48
 - Neurons
 - hypothalamic control of bone formation and, 403, 405-7
 - iron status and neural functioning, 43
 - Neuropeptide Y (NPY)
 - diabetes type 2 prevalence and, 364
 - hypothalamic control of bone formation and, 406
 - Neurotoxins
 - hypothalamic control of bone formation and, 406
 - Neurotransmitters
 - iron status and neural

- functioning, 41–42, 45, 47–53
- New World syndrome
 - diabetes type 2 prevalence and, 356
- Niger
 - iron status and neural functioning, 49
- Nitrogen balance
 - amino acid requirement determination and, 101, 103–6, 108, 110–13
- Nitrogen species
 - lutein and zeaxanthin protective role in eye, 182
- Nonesterified fatty acids (NEFAs)
 - milk fat synthesis
 - nutritional regulation and, 206, 212–13
- Nonheme iron absorption
 - dietary iron absorption and, 284
- North America
 - diabetes type 2 prevalence and, 348, 361, 365–66
- Norwalk-like virus
 - foodborne illness reduction and, 322, 325
- Nramp2 transporter
 - dietary iron absorption and, 283, 288
- Nucleus accumbens
 - iron status and neural functioning, 46
- Nutritional history
 - diet of US poor and minority communities
 - 100 years ago, 81–97
- Nutritive sweeteners
 - diabetes type 2 prevention and, 158
- O**
- Obesity
 - diabetes type 2 prevalence and, 345, 348, 353–54, 359–60, 362–66
 - diabetes type 2 prevention and, 147–55, 159, 162
 - gugulipid and, 307
 - hypothalamic control of bone formation and, 405
- ob/ob* mice
 - hypothalamic control of bone formation and, 406–8
 - metabolic pathway fluxes and, 391, 393–94
- Observational epidemiology
 - lutein and zeaxanthin protective role in eye, 188–89
- Oligodendrocytes
 - iron status and neural functioning, 43, 45
- Oncostatin M
 - hypothalamic control of bone formation and, 405
- Orlistat
 - diabetes type 2 prevention and, 150, 152
- Osteoblasts
 - hypothalamic control of bone formation and, 403–5, 408
- Osteoclasts
 - hypothalamic control of bone formation and, 403–4
- Osteopenia
 - hypothalamic control of bone formation and, 408–9
- Osteoporosis
 - hypothalamic control of bone formation and, 404, 409
- Outbreak detection
 - foodborne illness reduction and, 337–38
- Ovarian failure
 - galactosemia and, 59, 74
- Ovariectomy
 - hypothalamic control of bone formation and, 403, 409
- Overall obesity
 - diabetes type 2 prevention and, 152–53
- Oxidation
 - galactosemia and, 59, 63–64
 - lutein and zeaxanthin protective role in eye, 177–78
- Oxidative stress
 - diabetes type 2 prevention and, 160
 - iron status and neural functioning, 44
- P**
- Pacific Islanders
 - diabetes type 2 prevalence and, 348–49, 355, 365
- Pakistan
 - diabetes type 2 prevalence and, 348–49
- Paleonutrition
 - diabetes type 2 prevalence and, 351–52
- Pan troglodytes*
 - diabetes type 2 prevalence and, 350
- Papua, New Guinea
 - diabetes type 2 prevalence and, 349
- Parenteral nutrition
 - perioperative patient and nutrition, 263–74
- Partially hydrogenated vegetable oils (PHVOs)
 - milk fat synthesis
 - nutritional regulation and, 217
- Pathogenicity
 - foodborne illness reduction and, 315–41
- Penicillin

- foodborne illness reduction and, 326
 Perioperative patient nutrition in
 cost, 271-73
 introduction, 263-64
 postoperative nutrition support, 268-71
 preoperative nutrition support, 264-68
 unresolved issues, 273-74
 Peripheral mediator
 hypothalamic control of bone formation and, 403
 Permissive effects
 vitamin D and immune activation, 136
 Peru
 diabetes type 2 prevention and, 149
 pH
 dietary iron absorption and, 286
 Phenotype
 diabetes type 2 prevalence and, 345, 357-58, 366
 galactosemia and, 59, 75
 high bone mass, 409
 metabolic pathway fluxes and, 382, 390-91
 Phenylketonuria (PKU)
 amino acid requirement determination and, 105-6, 112
 Philippines
 diabetes type 2 prevalence and, 361
 Phosphorous
 vitamin D and immune activation, 117
 Phosphorylation
 hypothalamic control of bone formation and, 405
 Photoreceptors
 lutein and zeaxanthin protective role in eye, 171, 183, 191
 Physical activity
 diabetes type 2 prevention and, 147-48, 152-54, 162
 Plasmodium spp.
 diabetes type 2 prevalence and, 353
 Policy issues
 foodborne illness reduction and, 315, 332-36
 Polyunsaturated fatty acids (PUFAs)
 milk fat synthesis nutritional regulation and, 203, 207-8, 220
 Pons
 iron status and neural functioning, 43
 Population surveillance
 foodborne illness reduction and, 337-38
 Positive energy balance
 diabetes type 2 prevalence and, 364-66
 Postoperative nutrition support
 perioperative patient and nutrition, 263, 268-71
 Potassium
 diabetes type 2 prevention and, 160
 Poverty
 diet of US poor and minority communities
 100 years ago, 81-97
 Prebiotics
 trophic and cytoprotective nutrition for intestine, 245-48
 Pregnancy
 amino acid requirement determination and, 113
 iron status and neural functioning, 42, 49
 Pregnane X receptor (PXR)
 gugulipid and, 308-10
 Prenatal phenotypic programming
 diabetes type 2 prevalence and, 357-58
 Preoperative nutrition support
 perioperative patient and nutrition, 263-68
 Preschool children
 iron status and neural functioning, 41, 51
 Prevention
 diabetes type 2 and, 147-62
 Prevention-based regulatory approaches
 foodborne illness reduction and, 338
 Private sector responsibilities
 foodborne illness reduction and, 332-33
 Probiotics
 perioperative patient and nutrition, 271
 Processive insertion
 selenoprotein synthesis and, 27-28
 Prokaryotes
 selenoprotein synthesis and, 17, 21-24
 Pro-oxidation
 lutein and zeaxanthin protective role in eye, 181-83
 Propionibacterium spp.
 milk fat synthesis nutritional regulation and, 216
 Propranolol
 gugulipid and, 308
 hypothalamic control of bone formation and, 408-9
 Prostaglandins
 trophic and cytoprotective nutrition for intestine, 243-44
 Protector gene

galactosemia and, 75-76

Protein

dietary

diabetes type 2
prevention and, 159

Protein-sparing therapy

perioperative patient and
nutrition, 265, 269

Puberty

hypothalamic control of
bone formation and, 403

Q

Quaternary complex

selenoprotein synthesis
and, 22-23

R

Radiation

trophic and cytoprotective
nutrition for intestine,
235-38, 242, 245

Raw foods

foodborne illness reduction
and, 329

Reactive oxygen species

lutein and zeaxanthin
protective role in eye,
171-93

Redox reactions

luminal
dietary iron absorption
and, 287

Reflectometry

lutein and zeaxanthin
protective role in eye,
186-87

Reflex sympathetic dystrophy

hypothalamic control of
bone formation and,
409

Regulation

dietary iron absorption and,
285-95
milk fat synthesis
nutritional regulation and,
203-20

selenoprotein synthesis

and, 17-34
vitamin D and immune
activation, 117-36

Regulatory issues

foodborne illness reduction
and, 315, 332-36

Remodeling

bone

hypothalamic control of
bone formation and,
403-4

Reproduction

hypothalamic control of
bone formation and,
403-5

Resonance Raman

spectroscopy
lutein and zeaxanthin
protective role in eye,
187-88

Retina

lutein and zeaxanthin
protective role in eye,
171-93

Retinitis pigmentosa

lutein and zeaxanthin
protective role in eye,
190-91

Retinoids

history of research,
1-14

N-Retinyl-*N*-retinylidene

ethanolamine (A2E)
lutein and zeaxanthin
protective role in eye,
191, 193

Ribosomes

selenoprotein synthesis
and, 17-18

Risk-based system for food safety

foodborne illness reduction
and, 339-340

Rotavirus

foodborne illness reduction
and, 323

Rumen

milk fat synthesis

nutritional regulation and,
203-4, 207-10, 214,
216-17, 219-20

Russia

diabetes type 2 prevalence
and, 365

S

Saccharomyces cerevisiae

selenoprotein synthesis
and, 33

Salmonella spp.

foodborne illness reduction
and, 320-21, 325-26,
328-29, 337, 340

SBP2 protein

selenoprotein synthesis
and, 26, 33

SECIS element

selenoprotein synthesis
and, 17, 22-29,
32-33

Sedentary lifestyles

diabetes type 2 prevalence
and, 345-66

SelB elongation factor

selenoprotein synthesis
and, 21-22

Selenium

lutein and zeaxanthin
protective role in eye, 182

Selenoprotein synthesis

cis-acting sequences,
24-26
concentration of factors,
23-24
conclusions, 33-34
eEFsec, 27
efficiency, 23-24
Escherichia coli, 23-24
hierarchy, 32
introduction, 18
kinetics, 23-24
limiting factors as key
point of regulation, 31


- mammalian selenoproteins,
19
 function, 20
 identification, 20
 regulation, 31–33
mRNA stability, 32–33
perspectives, 33–34
processive insertion, 27–28
quaternary complex,
22–23
regulation, 23–24
SBP2, 26–33
SECIS element, 24–26
SelB, 21–22
selenium, 19, 31–33
selenocysteine
 efficiency of insertion,
 29–31
 eukaryotes, 24–25
 function, 19
 insertion, 20–31
 model for Sec insertion,
 23
 prokaryotes, 21–24
 structure, 19
 termination, 24
 translational decoding of
 UGA as, 20–21
tRNA, 21
unique aspects of Sec
insertion compared to
normal protein
synthesis, 20–21
trans-acting proteins, 26
UGA codon, 29, 31
unanswered questions,
28–29
Self-tolerance
 vitamin D and immune
 activation, 136
sel genes
 selenoprotein synthesis
 and, 21
Shigella spp.
 foodborne illness reduction
 and, 321, 325, 329, 331,
 337
Short bowel syndrome
 trophic and cytoprotective
 nutrition for intestine,
 229, 234–35, 244–45
Short-chain fatty acids
 (SCFAs)
 trophic and cytoprotective
 nutrition for intestine,
 229, 245–48
Signaling
 vitamin D and immune
 activation, 125–27
Sirolimus
 vitamin D and immune
 activation, 133
SLC 11A3 protein
 dietary iron absorption and,
 289–90
Slow turnover proteins
 metabolic pathway fluxes
 and, 379, 398
Small intestine
 gugulipid and, 309
Specialized nutritional
 support (SNS)
 perioperative patient and
 nutrition, 263–74
Speciation
 dietary iron absorption and,
 285–86
Spoilage
 foodborne illness reduction
 and, 328–29
Stable isotope-
 mass/spectrometric
 methods
 metabolic pathway fluxes
 and, 379–99
Staphylococcus spp.
 foodborne illness reduction
 and, 321
Starch
 diabetes type 2 prevention
 and, 158
Stat3 molecule
 hypothalamic control of
 bone formation and, 405
State responsibilities
 foodborne illness reduction
 and, 335
Static concentrations
 metabolic pathway fluxes
 and, 383–84
Steroid hormones
 history of research, 1, 12
St. Kitts and Nevis
 diabetes type 2 prevalence
 and, 349
Streptococcus spp.
 foodborne illness reduction
 and, 321, 326
Stress
 metabolic changes and, 1,
 6–7
Striatum
 iron status and neural
 functioning, 41, 46, 48, 50
Subsistence energy costs
 diabetes type 2 prevalence
 and, 360–61
Supersizing foods
 diabetes type 2 prevalence
 and, 362
Supplements
 diabetes type 2 prevention
 and, 160–61
 lutein and zeaxanthin
 protective role in eye, 184
Sympathetic nervous system
 (SNS)
 hypothalamic control of
 bone formation and, 403,
 407–9
Syndrome X
 diabetes type 2 prevalence
 and, 345, 357, 365

T
Tacrolimus
 vitamin D and immune
 activation, 133
Taenia spp.
 foodborne illness reduction
 and, 324

- Taste
 diabetes type 2 prevalence and, 354-55
- Termination
 selenoprotein synthesis and, 17, 24
- Tetracycline
 gugulipid and, 308
- Th-1-type cellular immune responses
 vitamin D and immune activation, 135
- Thailand
 diabetes type 2 prevalence and, 359, 366
 iron status and neural functioning, 52
- Thrifty genotypes
 diabetes type 2 prevalence and, 345, 355-56, 366
- Thymopentine
 perioperative patient and nutrition, 271
- Thyroid gland
 gugulipid and, 307-8
- Tissue metabolism
 milk fat synthesis
 nutritional regulation and, 203-4
- T lymphocytes
 vitamin D and immune activation, 117, 123-24, 136
- α -Tocopherol
 diabetes type 2 prevention and, 160
- Tonga
 diabetes type 2 prevalence and, 349
- Toxoplasma gondii*
 foodborne illness reduction and, 322, 324-25
- trans*-acting factors
 selenoprotein synthesis and, 17-18, 26, 28
- trans* fatty acid theory
 milk fat synthesis
 nutritional regulation and, 214-16
- Transfer
 dietary iron absorption and, 292-293
- Transferrin
 iron status and neural functioning, 43-44
- Transgenics
 hypothalamic control of bone formation and, 404-5
 metabolic pathway fluxes and, 382
- Translational decoding
 selenoprotein synthesis and, 17, 20-21
- Transplantation
 vitamin D and immune activation, 117, 130-31
- Transport genes
 dietary iron absorption and, 287-88
- Trichinella spiralis*
 foodborne illness reduction and, 322, 324
- Trinidad and Tobago
 diabetes type 2 prevalence and, 349
- Trophic/cytoprotective
 nutrition
 for intestine
 antioxidants, 240-42
 arginine, 238-40
 chemotherapy, 235-42, 245
 critical illness, 235-38, 242, 245
 dietary fiber, 245-48
 fatty acids, 243-44
 glutamine, 232-38
 glutathione, 240-42
 glycine, 238
 gut mucosal growth and adaptation, 230-32
 histidine, 238
 inflammatory bowel disease, 233-44
 prebiotics, 245-48
 prostaglandins, 243-44
 radiation, 235-42, 245
 short bowel syndrome, 234-35, 244-45
 short-chain fatty acids, 245-48
 summary, 249-50
 vitamin A, 242-43
 zinc, 248-49
- Tryptophan oxygenase
 history of research, 1, 8, 10
- 24-hour balance
 amino acid requirement
 determination and, 101, 103-5, 107, 109-10
- Two-phase linear regression
 crossover
 amino acid requirement
 determination and, 101, 108
- U
- UDP-galactose
 galactosemia and, 59, 63, 66-68, 70-73, 75
- UGA codon
 selenoprotein synthesis and, 17-18, 20-21, 29, 31
- United Kingdom
 iron status and neural functioning, 50
- United States
 diabetes type 2 prevalence and, 347-48, 358, 360-63, 365-66
 diabetes type 2 prevention and, 149, 153, 155-59
 foodborne illness reduction and, 315-41
 poor and minority communities 100 years ago
 African American
 diets, 84-87
 American-born poor, 90

- Appalachia, 87-89
 conclusions, 97
 discussion, 95-97
 early dietaries and their method, 82-84
 Europeans, 91-94
 French Canadians, 91
 immigrants, 91-94
 introduction, 82
 Mexican Americans, 89
 mountaineers, 87-89
 poor urban and immigrant households, 89-94
- Urban households
 diet of US poor and minority communities
 100 years ago, 89-94
- Uridine controversy
 galactosemia and, 75
- V**
- Vegetables
 dark-green leafy
 lutein and zeaxanthin
 protective role in eye,
 171, 184-85, 188-89
 diabetes type 2 prevention
 and, 159-60
- Ventro-medial hypothalamic
 (VMH) nucleus
 hypothalamic control of
 bone formation and,
 406-7
- Very-low-density lipoprotein
 (VLDL)
 metabolic pathway fluxes
 and, 395-98
- Vibrio* spp.
 foodborne illness reduction
 and, 321-22, 337
- Viruses
 foodborne illness reduction
 and, 322-23, 325
- Vitamin A
 history of research, 1,
 11-14
- trophic and cytoprotective
 nutrition for intestine,
 229, 242-43
- Vitamin B₁₂
 history of research, 7
- Vitamin C
 lutein and zeaxanthin
 protective role in eye,
 182, 190
- Vitamin D and analogs
 immune activation and
 antigen presentation
 autoimmunity, 135-36
 B lymphocytes,
 124-25
 clinical applications,
 131-33
 cognate immunity,
 118-19
 combined effects with
 other
 immunomodulatory
 agents, 133-34
 conclusions, 136
 cross-talk, 118-19
 dendritic cells, 120-36
 dietary influences, 134
 experimental models of
 immune-mediated
 disease, 127-31
 genetically-based
 autoimmune disease,
 127-29
 hypercalcemia, 132, 134
 immune cell types,
 120-25
 immune system
 regulation, 118-19
 in vitro vs in vivo
 potency, 131-32
 induced
 immune-mediated
 disease, 129-30
 initial observations,
 119-20
 innate immunity, 11-19,
 135
- macrophages, 120-22,
 135
 modulation of
 intracellular signaling
 in immune cells,
 125-27
 monocytes, 120-22
 NK cells, 124-25
 permissive effects, 136
 physiological roles,
 135-36
 self-tolerance, 136
 Th-1-type cellular
 immune responses,
 135-36
 Th-2 T cells, 136
 therapeutic
 considerations,
 131-33
 timing and duration of
 therapy, 132-33
 T lymphocytes, 123-24
 transplantation, 130-31
 T_{reg}-type T-cells, 136
 vitamin D deficiency,
 120
 vitamin D receptors in
 immune system cells,
 119-20
 vitamin D therapy,
 127-31
- Vitamin E
 diabetes type 2 prevention
 and, 160
 lutein and zeaxanthin
 protective role in eye,
 182, 190
- Volatile fatty acids (VFAs)
 milk fat synthesis
 nutritional regulation and,
 208-10
- W**
- Weight loss
 diabetes type 2 prevention
 and, 147-48, 150-55,
 162

- perioperative patient and
nutrition, 264, 269,
273-74
- Western lifestyles
diabetes type 2 prevalence
and, 345-66
- Women
iron status and neural
functioning, 42, 49
- X**
- Xanthophylls
lutein and zeaxanthin
protective role in eye,
171-93
- Xerophthalmia
history of research,
13-14
- Y**
- Yeast
selenoprotein synthesis
and, 33
- Yersinia enterocolitica*
foodborne illness reduction
and, 322, 325, 328,
337
- Z**
- Zanzibar
iron status and neural
functioning, 51
- Zeaxanthin
lutein and zeaxanthin
protective role in eye,
171-93
- Zinc
diabetes type 2 prevention
and, 160
lutein and zeaxanthin
protective role in eye,
188, 190
trophic and cytoprotective
nutrition for intestine,
229, 248-49





CONTENTS

FRONTISPIECE— <i>Frank Chytil</i>	xiv
ROUGH AND ROCKY ROAD TO THE RETINOID REVOLUTION, <i>Frank Chytil</i>	1
MECHANISM AND REGULATION OF SELENOPROTEIN SYNTHESIS, <i>Donna M. Driscoll and Paul R. Copeland</i>	17
IRON STATUS AND NEURAL FUNCTIONING, <i>John L. Beard and James R. Connor</i>	41
INSIGHTS INTO THE PATHOGENESIS OF GALACTOSEMIA, <i>Nancy D. Leslie</i>	59
DIET AND NUTRITION IN POOR AND MINORITY COMMUNITIES IN THE UNITED STATES 100 YEARS AGO, <i>Robert Dirks</i>	81
DIFFERENT APPROACHES TO DEFINE INDIVIDUAL AMINO ACID REQUIREMENTS, <i>Paul B. Pencharz and Ronald O. Ball</i>	101
VITAMIN D AND ITS ANALOGS AS REGULATORS OF IMMUNE ACTIVATION AND ANTIGEN PRESENTATION, <i>Matthew D. Griffin, Nianzeng Xing, and Rajiv Kumar</i>	117
NUTRITION AND PREVENTION OF TYPE 2 DIABETES, <i>T. Costacou and E.J. Mayer-Davis</i>	147
BIOLOGIC MECHANISMS OF THE PROTECTIVE ROLE OF LUTEIN AND ZEAXANTHIN IN THE EYE, <i>Norman I. Krinsky, John T. Landrum, and Richard A. Bone</i>	171
NUTRITIONAL REGULATION OF MILK FAT SYNTHESIS, <i>Dale E. Bauman and J. Mikko Griinari</i>	203
TROPHIC AND CYTOPROTECTIVE NUTRITION FOR INTESTINAL ADAPTATION, MUCOSAL REPAIR, AND BARRIER FUNCTION, <i>Thomas R. Ziegler, Mary E. Evans, Concepción Fernández-Estívariz, and Dean P. Jones</i>	229
NUTRITION IN THE PERIOPERATIVE PATIENT, <i>Lyn Howard and Christopher Ashley</i>	263
PHYSIOLOGY AND MOLECULAR BIOLOGY OF DIETARY IRON ABSORPTION, <i>Silvia Miret, Robert J. Simpson, and Andrew T. McKie</i>	283

GUGULIPID: A NATURAL CHOLESTEROL-LOWERING AGENT, <i>Nancy L. Urizar and David D. Moore</i>	303
CHALLENGES AND APPROACHES TO REDUCING FOODBORNE ILLNESS, <i>Catherine E. Woteki and Brian D. Kineman</i>	315
DIETARY, EVOLUTIONARY, AND MODERNIZING INFLUENCES ON THE PREVALENCE OF TYPE 2 DIABETES, <i>Leslie Sue Lieberman</i>	345
IN VIVO MEASUREMENT OF FLUXES THROUGH METABOLIC PATHWAYS: THE MISSING LINK IN FUNCTIONAL GENOMICS AND PHARMACEUTICAL RESEARCH, <i>Marc K. Hellerstein</i>	379
COMMON ENDOCRINE CONTROL OF BODY WEIGHT, REPRODUCTION, AND BONE MASS, <i>Shu Takeda, Florent Eleftheriou, and Gerard Karsenty</i>	403
INDEXES	
Subject Index	413
Cumulative Index of Contributing Authors, Volumes 19–23	433
Cumulative Index of Chapter Titles, Volumes 19–23	436

ERRATA

An online log of corrections to *Annual Review of Nutrition* chapters
(if any, 1997 to the present) may be found at <http://nutr.annualreviews.org/>

